Cargando…
Tamoxifen treatment in premenopausal breast cancer patients may be associated with ovarian overstimulation, cystic formations and fibroid overgrowth.
Autores principales: | Cohen, I., Rosen, D. J., Altaras, M., Beyth, Y., Shapira, J., Yigael, D. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1994
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968870/ https://www.ncbi.nlm.nih.gov/pubmed/8123501 |
Ejemplares similares
-
Overstimulated and ineffective
por: Van Epps, Heather L.
Publicado: (2005) -
Ovarian cancer risk in premenopausal and perimenopausal women treated with Tamoxifen: a case–control study
por: Swerdlow, A J, et al.
Publicado: (2007) -
Blood cadmium and volume of uterine fibroids in premenopausal women
por: Ye, Shinhee, et al.
Publicado: (2017) -
Tamoxifen-induced ovarian hyperstimulation during premenopausal hormonal therapy for breast cancer in Japanese women
por: Yamazaki, Rena, et al.
Publicado: (2015) -
Inhibin Inactivation in Female Mice Leads to Elevated FSH Levels, Ovarian Overstimulation, and Pregnancy Loss
por: Walton, Kelly L, et al.
Publicado: (2022)